Differential patient stratification by the breast cancer index Hox613/1L17BR ratio vs recurrence score (RS) plus quantitative ER expression in hormone receptor positive, node negative breast cancer

被引：0
|
作者：
Naughton, M. J.
Schroeder, B. E.
Operana, T. N.
Zhang, Y.
Schnabel, C. A.
机构：
[1] Washington Univ, St Louis, MO USA
[2] BioTheranostics Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-08-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-09
引用
收藏
页数：1
相关论文
共 22 条
  • [1] Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer
    Sestak, Ivana
    Zhang, Yi
    Schroeder, Brock E.
    Schnabel, Catherine A.
    Dowsett, Mitch
    Cuzick, Jack
    Sgroi, Dennis
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5043 - 5048
  • [2] Recurrence Score (RS) and Treatment Decisions in Node-positive (N plus ), Estrogen Receptor-positive (ER plus ) Breast Cancer Patients in Israel
    Stemmer, S. M.
    Lieberman, N.
    Efrat, N.
    Geffen, D. B.
    Steiner, M.
    Soussan-Gutman, L.
    Merling, S.
    Rizel, S.
    Klang, S. H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [3] German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER plus ) node negative (N0) and node positive (N plus ) early breast cancer
    Blohmer, J. -U.
    Kuehn, T.
    Rezai, M.
    Kuemmel, S.
    Warm, M.
    Eggemann, H.
    Friedrichs, K.
    Eiermann, W.
    BREAST, 2011, 20 : S46 - S46
  • [4] Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study
    Zhang, Y.
    Sestak, I.
    Schroeder, B. E.
    Dowsett, M.
    Cuzick, J.
    Schnabel, C. A.
    Sgroi, D. C.
    CANCER RESEARCH, 2016, 76
  • [5] Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer
    Schroeder, B. E.
    Zhang, Y.
    Stal, O.
    Fornander, T.
    Brufsky, A.
    Sgroi, D. C.
    Schnabel, C. A.
    CANCER RESEARCH, 2017, 77
  • [6] Comparison of risk stratification of ER-positive, node-negative breast cancer patients by Oncotype DX versus molecular grade index and HOXB13/IL17BR ratio
    Sgroi, D.
    Hameed, O.
    Hattab, E.
    Chang, B.
    Moulis, S.
    Steffel, L.
    Salunga, R.
    Ma, X.
    Erlander, M.
    Goss, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR plus ), Node Negative (NO) and Node Positive (N plus ) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC).
    de Boer, R. H.
    Baker, C.
    Speakman, D.
    Mann, B.
    CANCER RESEARCH, 2011, 71
  • [8] The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor positive (ER plus ), lymph node positive (LN plus ) breast cancer (BC) in Ireland: A national, multi-centre, prospective study
    Mullally, William J.
    Bracken-Clarke, Dara
    Padmore, Andrew
    O'Reilly, Seamus
    O'Mahony, Deirdre
    Walshe, Janice
    Kennedy, John
    Gupta, Rajnish
    Kelly, Cathy
    O'Connor, Miriam
    Duffy, Karen
    Keane, Maccon
    Hennessy, Bryan T.
    Morris, Patrick G.
    CANCER RESEARCH, 2020, 80 (04)
  • [9] Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN plus ) hormone receptor-positive (HR plus ) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries
    Miller, D. P.
    Roberts, M.
    Petkov, V. I.
    Shak, S.
    Howlader, N.
    Cronin, K.
    Penberthy, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category
    Le, D.
    Chia, S.
    Simmons, C.
    Speers, C.
    Gondara, L.
    Nichol, A.
    Lohrisch, C.
    Gelmon, K. A.
    CANCER RESEARCH, 2019, 79 (04)
123